Cagrilintide — Long-acting amylin analog (amylin receptor agonist)

The rationale for cagrilintide is mechanistic complementarity with GLP-1 agonists: amylin receptors are in the area postrema and hypothalamus (different circuits from GLP-1's arcuate nucleus pathway), enabling additive appetite suppression without receptor saturation. REDEFINE 1 Phase 3 trial (CagriSema 2.4/2.4mg): interim data showed ~22% weight loss — comparable to tirzepatide 15mg. Monotherapy cagrilintide produces modest weight loss (~8%), but the combination with semaglutide demonstrates synergism. Amylin analog safety is well-established via pramlintide (Symlin, FDA-approved since 2005), reducing new mechanism-related risk concerns.

Overview

This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.

Compound Class

Long-acting amylin analog (amylin receptor agonist)

Mechanism of Action

Cagrilintide is a fatty acid-acylated analog of human amylin (islet amyloid polypeptide, IAPP), co-secreted with insulin from pancreatic β-cells. Amylin receptor activation acts via a distinct, complementary mechanism to GLP-1: activates area postrema (brainstem satiety center) independently of GLP-1 receptors, slows gastric emptying more potently than GLP-1 agonists, suppresses postprandial glucagon, reduces food intake through central circuits different from hypothalamic GLP-1 pathways. Critically, amylin and GLP-1 receptors are located in different brain regions — combining both (CagriSema) produces additive rather than redundant suppression of appetite. Long-acting formulation (half-life ~8 days) achieved via fatty acid acylation enabling albumin binding, analogous to semaglutide's design.

Regulatory Status

Investigational — Phase 3 REDEFINE trials ongoing; CagriSema FDA submission anticipated 2025-2026

Evidence Level

Moderate-High — Phase 3 REDEFINE program ongoing; Phase 2 monotherapy +8% weight loss, CagriSema +16% at interim